Education
About Us
Working with TipRanks
Follow Us
Hikma Pharma (HKMPY)
:HKMPY
RESEARCH TOOLSreports
HKMPY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$45.26 - $58.61
Previous CloseN/A
Volume13.00
Average Volume (3M)31.00
Market Cap
$5.85B
Enterprise Value$7.02B
Total Cash (Recent Filing)$213.00M
Total Debt (Recent Filing)$1.31B
Price to Earnings (P/E)16.5
Beta0.38
Next Earnings
Aug 07, 2025EPS EstimateN/A
Last Dividend Ex-Date
Mar 21, 2025Dividend Yield3.63%
Share Statistics
EPS (TTM)1.19
Shares Outstanding110,943,230
10 Day Avg. Volume67
30 Day Avg. Volume31
Financial Highlights & Ratios
PEG Ratio0.62
Price to Book (P/B)2.56
Price to Sales (P/S)0.00
P/FCF Ratio14.79
Enterprise Value/Market Cap1.20
Enterprise Value/Revenue0.60
Enterprise Value/Gross Profit5.14
Enterprise Value/Ebitda2.54
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Hikma Pharmaceuticals News
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.02%
Mutual Funds
― Other Institutional Investors
99.98% Public Companies and
Individual Investors
HKMPY FAQ
What was Hikma Pharma’s price range in the past 12 months?
Hikma Pharma lowest stock price was $45.26 and its highest was $58.61 in the past 12 months.
What is Hikma Pharma’s market cap?
Hikma Pharma’s market cap is $5.85B.
When is Hikma Pharma’s upcoming earnings report date?
Hikma Pharma’s upcoming earnings report date is Aug 07, 2025 which is in 19 days.
How were Hikma Pharma’s earnings last quarter?
Hikma Pharma released its earnings results on Feb 26, 2025. The company reported $1.194 earnings per share for the quarter, beating the consensus estimate of N/A by $1.194.
Is Hikma Pharma overvalued?
According to Wall Street analysts Hikma Pharma’s price is currently Overvalued.
Does Hikma Pharma pay dividends?
Hikma Pharma pays a Semiannually dividend of $1.559 which represents an annual dividend yield of 3.63%. See more information on Hikma Pharma dividends here
What is Hikma Pharma’s EPS estimate?
Hikma Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hikma Pharma have?
Hikma Pharma has 110,943,230 shares outstanding.
What happened to Hikma Pharma’s price movement after its last earnings report?
Hikma Pharma reported an EPS of $1.194 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -5.853%.
Which hedge fund is a major shareholder of Hikma Pharma?
Currently, no hedge funds are holding shares in HKMPY
Hikma Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
14.37%
12-Months-Change
Fundamentals
Return on Equity
15.87%
Trailing 12-Months
Asset Growth
9.68%
Trailing 12-Months
Company Description
Hikma Pharma
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.
Technical Analysis
Dr Reddy's Laboratories
―
Viatris
―
Perrigo Company
―
Teva Pharmaceutical
―
Amneal Pharmaceuticals
―